Prevention of relapse after allogeneic hematopoietic cell transplantation by donor and cell source selection. Bone Marrow Transplant 2018 Dec;53(12):1498-1507
Date
05/26/2018Pubmed ID
29795435Pubmed Central ID
PMC7286200DOI
10.1038/s41409-018-0218-1Scopus ID
2-s2.0-85047352097 (requires institutional sign-in at Scopus site) 8 CitationsAbstract
Allogeneic hematopoietic cell transplantation (HCT) is the most established form of cancer immunotherapy and has been successfully applied for the treatment and cure of otherwise lethal neoplastic blood disorders. Cancer immune surveillance is mediated to a large extent by alloreactive T and natural killer (NK) cells recognizing genetic differences between patient and donor. Profound insights into the biology of these effector cells has been obtained over recent years and used for the development of innovative strategies for intelligent donor selection, aiming for improved graft-versus-leukemia effect without unmanageable graft-versus-host disease. The cellular composition of the stem cell source plays a major role in modulating these effects. This review summarizes the current state-of the-art of donor selection according to HLA, NK alloreactivity and stem cell source.
Author List
Fleischhauer K, Hsu KC, Shaw BEAuthor
Bronwen E. Shaw MBChB, PhD Center Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Donor SelectionHematopoietic Stem Cell Transplantation
Recurrence
Tissue Donors
Transplantation Conditioning
Transplantation, Homologous
